pharma · Rectal Cancer · Fanconi Anemia · RCKT
Rocket Pharmaceuticals
Rocket Pharmaceuticals B.V.
Rocket Pharmaceuticals is a pharma organization headquartered in Cranbury, USA. It trades on NYSE under ticker RCKT. Primary therapeutic focus areas include Rectal Cancer, Fanconi Anemia, Danon Disease, PKP2 Arrhythmogen
9 Cedarbrook Dr, Cranbury, New Jersey 08512, US HQ
2015 Founded
226 Employees
Public company Type
RCKT · NYSE Ticker
Company details
- Status
- Public
- HQ
- 9 Cedarbrook Dr, Cranbury, New Jersey 08512, US
- Founded
- 2015
- Employees
- 226
- Programs
- 11
- Drugs
- 10
- Patents
- 1
RP-L201
Phase 2 · mab · Leukocyte Adhesion Defect - Type I
RP-L201 for Leukocyte Adhesion Defect - Type I is a Phase 2 program (mab) at Rocket Pharmaceuticals B.V. with 2 ClinicalTrials.gov record(s).
Internal code RP-L201-0318
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Rocket Pharmaceuticals B.V.
- Phase
- Phase 2
- Modality
- mab
- Indication
- Leukocyte Adhesion Defect - Type I
- Status
- completed
- Trials
- 2